These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27457067)

  • 1. Immunological Characteristics of a Patient With Belatacept-Resistant Acute Rejection After Face Transplantation.
    Krezdorn N; Murakami N; Pomahac B; Riella LV
    Am J Transplant; 2016 Nov; 16(11):3305-3307. PubMed ID: 27457067
    [No Abstract]   [Full Text] [Related]  

  • 2. De novo belatacept in clinical vascularized composite allotransplantation.
    Cendales LC; Ruch DS; Cardones AR; Potter G; Dooley J; Dore D; Orr J; Ruskin G; Song M; Chen DF; Selim MA; Kirk AD
    Am J Transplant; 2018 Jul; 18(7):1804-1809. PubMed ID: 29723921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belatacept in the treatment of acute T-cell mediated rejection and maintenance immunosuppression in a paediatric kidney transplant recipient.
    Soraru J; Sheriff D; Rajakaruna R; Larkins N
    Nephrology (Carlton); 2022 Jul; 27(7):641-642. PubMed ID: 35289023
    [No Abstract]   [Full Text] [Related]  

  • 4. Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types.
    Perez CP; Patel N; Mardis CR; Meadows HB; Taber DJ; Pilch NA
    Transplantation; 2018 Sep; 102(9):1440-1452. PubMed ID: 29787522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept-Resistant Rejection Is Associated With CD28
    Mathews DV; Wakwe WC; Kim SC; Lowe MC; Breeden C; Roberts ME; Farris AB; Strobert EA; Jenkins JB; Larsen CP; Ford ML; Townsend R; Adams AB
    Am J Transplant; 2017 Sep; 17(9):2285-2299. PubMed ID: 28502128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Pretransplant Frequency of CD28
    Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
    Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
    Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
    Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.
    Zhang H; Wang Z; Zhang J; Gui Z; Han Z; Tao J; Chen H; Sun L; Fei S; Yang H; Tan R; Chandraker A; Gu M
    Front Immunol; 2021; 12():618737. PubMed ID: 33732243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
    Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
    Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cell Subsets Predicting Belatacept-Resistant Rejection: Finding the Root Where the Trouble Starts.
    Wekerle T
    Am J Transplant; 2017 Sep; 17(9):2235-2237. PubMed ID: 28613437
    [No Abstract]   [Full Text] [Related]  

  • 13. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.
    Samy KP; Anderson DJ; Lo DJ; Mulvihill MS; Song M; Farris AB; Parker BS; MacDonald AL; Lu C; Springer TA; Kachlany SC; Reimann KA; How T; Leopardi FV; Franke KS; Williams KD; Collins BH; Kirk AD
    Am J Transplant; 2017 May; 17(5):1193-1203. PubMed ID: 27888551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
    Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
    Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and limitations of belatacept in 4 hand-transplanted patients.
    Grahammer J; Weissenbacher A; Zelger BG; Zelger B; Boesmueller C; Ninkovic M; Mühlbacher A; Peschel I; Brandacher G; Öfner D; Schneeberger S
    Am J Transplant; 2017 Dec; 17(12):3228-3235. PubMed ID: 28742936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
    Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
    Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.
    Woodle ES; Kaufman DB; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Am J Transplant; 2020 Apr; 20(4):1039-1055. PubMed ID: 31680394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study.
    Darres A; Ulloa C; Brakemeier S; Garrouste C; Bestard O; Del Bello A; Sberro Soussan R; Dürr M; Budde K; Legendre C; Kamar N
    Transplantation; 2018 Sep; 102(9):1545-1552. PubMed ID: 29570163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.